TEVA Teva Pharma Industries Ltd
Company Analysis
Latest News
Teva Upgraded to Investment Grade on Branded Growth and Debt Reduction
Moody's Ratings upgraded Teva Pharmaceutical Industries' issuer rating to Baa3 from Ba1, assigning a stable outlook. This upgrade returns the company to...
🔴 Teva Pharma is trading 5.9% down today as investors take profits following its Q2 earnings rally
Teva Pharma is trading at $33.31 (5.9% down) in after-hours trading, pulling back after a sharp two-day rally that followed its Q2 2026 earnings release. •...
🟢 Teva Pharma is trading 11.3% up today as innovative brands hit $1B revenue milestone
Teva Pharma is trading 11.3% up today at $35.26 after its Q2 2026 earnings highlighted a major strategic milestone for its branded portfolio. • Innovative...
Teva's Branded Drug Trio Tops $1 Billion in a Quarter — But Can a Generics Giant Really Become an Innovation Story?
Shares surged 6.1% to $33.60 in pre-market as Teva Pharmaceutical delivered second-quarter results that smashed expectations on its most closely watched...
🟢 Teva Pharma is trading 6.1% up today on a Q2 revenue beat and strong innovative brand growth
Teva Pharma is trading at $33.60 (+6.09%) in pre-market following second-quarter 2026 results that highlighted a successful pivot toward its branded...
Teva Pharmaceutical Industries' second quarter revenue beats on 43% innovative brand growth, though EPS misses due to acquisition costs.
Teva reported second quarter 2026 revenues of $4.1 billion, a 1% decrease year-over-year, while non-GAAP EPS was $0.02, down from $0.66 in the prior-year...
Teva Pharma Industries Ltd Q2 2026 Earnings Preview: What Analysts Expect on July 29, 2026
Teva Pharma is expected to report Q2 2026 consensus revenue of $4.07 billion and non-GAAP EPS of $0.41, with its stock currently trading at $30.81,...
Teva Licenses Ocrevus Biosimilar, Pivoting Toward High-Margin Specialty Medicines
Teva Pharmaceutical Industries signed a global licensing agreement with Polpharma Biologics for a biosimilar candidate to Ocrevus. This treatment targets...
🔴 TEVA is trading 4.1% down today despite positive vitiligo program update, amidst macro-driven pressure
TEVA is trading 4.1% down at $33.24 today, as broader macro-driven weakness in the pharmaceutical sector weighs on investor sentiment, despite positive news...
Teva Pharma Industries Ltd Q1 2026 Earnings Preview: What Analysts Expect on May 13, 2026
Analysts expect Teva Pharma Industries to report Q1 2026 revenue of $3.87 billion and non-GAAP EPS of $0.55, with the stock currently priced at $36.10, roughly...
Teva's first quarter 2026 revenue of $4.0B beats estimates, driven by 41% AUSTEDO growth.
Teva reported first quarter revenue of approximately $4.0 billion and non-GAAP EPS of $0.53, slightly beating analyst expectations. The results were driven by...
Teva Pharma Industries Ltd Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
Analysts expect Teva to report Q1 2026 revenue of $3.92 billion and adjusted EPS of $0.52, while the current share price of $30.64 remains well below the...